Pilatus Biosciences Receives FDA Orphan Drug Designation for PLT012 in Liver Cancer
Pilatus Biosciences Inc. announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to its leading molecule, PLT012, for treating liver and…
Read More...
Read More...
